Reata Pharmaceuticals, Inc. RETA announced that it has completed its previously requested pre-new drug application (NDA) meeting with the FDA related to its Friedreich’s ataxia (“FA”) candidate, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback